Visceral leishmaniasis or Kala-azar (KA) is a Vector-Borne Disease (VBD) that remains the
second-largest parasitic killer across the globe (mortality rate: 75–95%). More than 60% of …

Leishmaniasis, a neglected tropical disease, encompasses a spectrum of clinical conditions
and poses a significant risk of infection to over one billion people worldwide. Visceral …

Leishmaniasis in Africa, which has been designated as a priority neglected tropical disease
by various global organizations, exerts its impact on millions of individuals, primarily …

Cutaneous and visceral leishmaniasis are public health problems in Africa, Asia, Europe,
and America. The treatment has a high cost and toxicity. Thus, this work aims to evaluate the …

In the absence of a vaccine, there is a need to find new drugs for the treatment of neglected
tropical diseases, such as leishmaniasis, that can overcome the many drawbacks of those …

There are three known clinical syndromes of leishmaniasis: cutaneous (CL),
mucocutaneous (MCL), and visceral disease (VL). In MCL and VL, treatment must be …

Nonspecific hypergammaglobulinemia (HGG) occurs in symptomatic human visceral
leishmaniasis (VL) caused by LL infantum. This study assessed this finding in experimental …

Background Our objective in this study is to determine the atypical clinical presentations of
cutaneous leishmaniasis (CL) patients diagnosed in Şanlıurfa province. Methods This …

Propolis is a natural product widely used in folk medicine. Among its various applications, its
antiparasitic properties stand out. Due to its great biodiversity, Brazil is a major producer of …

We aimed to estimate the diagnostic latency of patients with visceral leishmaniasis (VL). A
monocentric retrospective observational study was conducted including all confirmed cases …